Skip to main content
SpringerLink
Log in
SpringerLink
Log in

Sleep Aids

  • Chapter
  • First Online:
Comprehensive Treatment of Chronic Pain by Medical, Interventional, and Integrative Approaches

Abstract

Sleep is one of the most universal biological processes in existence. Depriving an organism of sleep altogether can be extremely detrimental and may even lead to death. Sleep is therefore considered necessary for life, but why this is so remains unclear. Sleep is subdivided into rapid eye movement (REM) sleep, which is characterized by high-frequency electroencephalogram (EEG) recordings and muscle atonia, and non-REM (slow-wave) sleep, characterized by low-frequency EEG recordings and body rest.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Rechtschaffen A, Bergmann BM, Everson CA, et al. Sleep deprivation in the rat. X. Integration and discussion of the findings. Sleep. 1989;12:68–87.

    PubMed  CAS  Google Scholar 

  2. Remy P, Doder M, Lees A, et al. Depression in Parkinson’s disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain. 2005;128:1314–22.

    Article  PubMed  Google Scholar 

  3. Stenberg D. Neuroanatomy and neurochemistry of sleep. Cell Mol Life Sci. 2007;64:1187–204.

    Article  PubMed  CAS  Google Scholar 

  4. Roth T. Insomnia: definition, prevalence, etiology, and consequences. J Clin Sleep Med. 2007;3:S7–10.

    PubMed  Google Scholar 

  5. Sivertsen B, Krokstad S, Mykletun A, Overland S. Insomnia symptoms and use of health care services and medications: the HUNT-2 study. Behav Sleep Med. 2009;7:210–22.

    Article  PubMed  Google Scholar 

  6. Kyle SD, Morgan K, Espie CA. Insomnia and health-related quality of life. Sleep Med Rev. 2010;14:69–82.

    Article  PubMed  Google Scholar 

  7. Joshi S. Non-pharmacological therapy for insomnia in the elderly. Clin Geriatr Med. 2008;24:107–19.

    Article  PubMed  Google Scholar 

  8. Morin CM. Insomnia: psychological assessment and management. New York: Guildford Press; 1993.

    Google Scholar 

  9. Yang CM, Lin SC, Hsu SC, Cheng CP. Maladaptive sleep hygiene practices in good sleepers and patients with insomnia. J Health Psychol. 2010;15:147–55.

    Article  PubMed  Google Scholar 

  10. AmericanAcademy of SleepMedicine. International classification of sleep disorders: diagnostic and coding manual. 2nd ed. Westchester: American Academy of Sleep Medicine; 2005.

    Google Scholar 

  11. Morin CM, Bootzin RR, Buysse DJ, et al. Psychological and behavioral treatment of insomnia: update of the recent evidence (1998–2004). Sleep. 2006;29:1398–414.

    PubMed  Google Scholar 

  12. Morin CM, Culbert JP, Schwartz SM. Nonpharmacological interventions for insomnia: a meta-analysis of treatment efficacy. Am J Psychiatry. 1994;151:1172–80.

    PubMed  CAS  Google Scholar 

  13. Morin CM, Hauri PJ, Espie CA, et al. Nonpharmacologic treatment of chronic insomnia. An American Academy of Sleep Medicine review. Sleep. 1999;22:1134–56.

    PubMed  CAS  Google Scholar 

  14. Murtagh DR, Greenwood KM. Identifying effective psychological treatments for insomnia: a meta-analysis. J Consult Clin Psychol. 1995;63:79–89.

    Article  PubMed  CAS  Google Scholar 

  15. Manber R, Kuo TF. Cognitive-behavioral therapies for insomnia. In: Lee-Chiong TL, Sateia MJ, Carskadon MA, editors. Sleep medicine. Philadelphia: Hanley & Belfus; 2002. p. 177–85.

    Google Scholar 

  16. Vitiello MV, Rybarczyk B, Von Korff M, Stepanski E. Cognitive behavioral therapy for insomnia improves sleep and decreases pain in older adults with co-morbid insomnia and osteoarthritis. J Clin Sleep Med. 2009;5:355–62.

    PubMed  Google Scholar 

  17. Sivertsen B, Omvik S, Pallesen S, et al. Cognitive behavioral therapy vs zopiclone for treatment of chronic primary insomnia in older adults: a randomized controlled trial. JAMA. 2006;295:2851–8.

    Article  PubMed  Google Scholar 

  18. Dolan DC, Taylor DJ, Bramoweth AD, Rosenthal LD. Cognitive-behavioral therapy of insomnia: a clinical case series study of patients with co-morbid disorders and using hypnotic medications. Behav Res Ther. 2010;48:321–7.

    Article  PubMed  Google Scholar 

  19. Morin CM, Colecchi C, Stone J, et al. Behavioral and pharmacological therapies for late-life insomnia: a randomized controlled trial. JAMA. 1999;281:991–9.

    Article  PubMed  CAS  Google Scholar 

  20. Irwin MR, Cole JC, Nicassio PM. Comparative meta-analysis of behavioral interventions for insomnia and their efficacy in middle-aged adults and in older adults 55+ years of age. Health Psychol. 2006;25:3–14.

    Article  PubMed  Google Scholar 

  21. Morin CM, Vallières A, Guay B, et al. Cognitive behavioral therapy, singly and combined with medication, for persistent insomnia: a randomized controlled trial. JAMA. 2009;301:2005–15.

    Article  PubMed  CAS  Google Scholar 

  22. Cao H, Pan X, Li H, Liu J. Acupuncture for treatment of insomnia: a systematic review of randomized controlled trials. J Altern Complement Med. 2009;15:1171–86.

    Article  PubMed  Google Scholar 

  23. Buscemi N, Vandermeer B, Friesen C, et al. Manifestations and management of chronic insomnia in adults. AHRQ publication no. 05-E021-2. 2008. Available at: www.ahrq.gov/downloads/pub/evidence/pdf/insomnia/insomnia.pdf. Accessed 27 May 2008.

  24. Ramakrishnan K, Scheid DC. Treatment options for insomnia. Am Fam Physician. 2007;76:517–26.

    PubMed  Google Scholar 

  25. Wafford KA, Ebert B. Emerging anti-insomnia drugs: tackling sleeplessness and the quality of wake time. Nat Rev Drug Discov. 2008;7:530–40.

    Article  PubMed  CAS  Google Scholar 

  26. Mitchell HA, Weinshenker D. Good night and good luck: norepinephrine in sleep pharmacology. Biochem Pharmacol. 2010;79:801–9.

    Article  PubMed  CAS  Google Scholar 

  27. Rudolph U, Crestani F, Benke D, et al. Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes. Nature. 1999;401:796–800.

    Article  PubMed  CAS  Google Scholar 

  28. Möhler H, Fritschy JM, Rudolph U. A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002;300(1):2–8.

    Article  PubMed  Google Scholar 

  29. Foster AC, Pelleymounter MA, Cullen MJ, et al. In vivo pharmacological characterization of indiplon, a novel pyrazolopyrimidine sedative hypnotic. J Pharmacol Exp Ther. 2004;311:547–59.

    Article  PubMed  CAS  Google Scholar 

  30. Petroski RE, Pomeroy JE, Das R, et al. Indiplon, is a high-affinity positive allosteric modulator with selectivity for α1 subunit-containing GABAA receptors. J Pharmacol Exp Ther. 2006;317:369–77.

    Article  PubMed  CAS  Google Scholar 

  31. Sanger DJ. The pharmacology and mechanisms of action of new generation, non-benzodiazepine hypnotic agents. CNS Drugs. 2004;18:9–15.

    Article  PubMed  CAS  Google Scholar 

  32. Wegner F, Deuther-Conrad W, Scheunemann M, et al. GABAA receptor pharmacology of fluorinated derivatives of the novel sedative-hypnotic pyrazolopyrimidine indiplon. Eur J Pharmacol. 2008;580:1–11.

    Article  PubMed  CAS  Google Scholar 

  33. Weinling E, McDougall S, Andre F, et al. Pharmacokinetic profile of a new modified release formulation of zolpidem designed to improve sleep maintenance. Fundam Clin Pharmacol. 2006;20:397–403.

    Article  PubMed  CAS  Google Scholar 

  34. Sanna E, Busonero F, Talani G, et al. Comparison of the effects of zaleplon, zolpidem, and triazolam at various GABAA receptor subtypes. Eur J Pharmacol. 2002;451:103–10.

    Article  PubMed  CAS  Google Scholar 

  35. Brunello N, Cooper J, Bettica P, et al. Differential pharmacological profiles of the GABAA receptor modulators zolpidem, zopiclone, eszopiclone, and (S)-desmethylzopiclone. In: Abstract Presented at the World Psychiatric Association International Congress (WPA), Florence; 2009.

    Google Scholar 

  36. Sivertsen B, Omvik S, Pallesen S, et al. Sleep and sleep disorders in chronic users of zopiclone and drug-free insomniacs. J Clin Sleep Med. 2009;5:349–54.

    PubMed  Google Scholar 

  37. Fernandez C, Maradeix V, Gimenez F, et al. Pharmacokinetics of zopiclone and its enantiomers in Caucasian young healthy volunteers. Drug Metab Dispos. 1993;21:1125–8.

    PubMed  CAS  Google Scholar 

  38. Fernandez C, Alet P, Davrinche C, et al. Stereoselective distribution and stereoconversion of zopiclone enantiomers in plasma and brain tissues in rats. J Pharm Pharmacol. 2002;54:335–40.

    Article  PubMed  CAS  Google Scholar 

  39. McMahon LR, Jerussi TP, France CP. Stereoselective discriminative stimulus effects of zopiclone in rhesus monkeys. Psychopharmacology (Berlin). 2003;165:222–8.

    CAS  Google Scholar 

  40. Fernandez C, Martin C, Gimenez F, Farinotti R. Clinical pharmacokinetics of zopiclone. Clin Pharmacokinet. 1995;29:431–41.

    Article  PubMed  CAS  Google Scholar 

  41. Carlson JN, Haskew R, Wacker J, et al. Sedative and anxiolytic effects of zopiclone’s enantiomers and metabolite. Eur J Pharmacol. 2001;415:181–9.

    Article  PubMed  CAS  Google Scholar 

  42. Najib J. Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia. Clin Therapy. 2006;28:491–516.

    Article  CAS  Google Scholar 

  43. Pandi-Perumal SR, Srinivasan V, Spence DW, Cardinali DP. Role of the melatonin system in the control of sleep: therapeutic implications. CNS Drugs. 2007;21:995–1018.

    Article  PubMed  CAS  Google Scholar 

  44. Reiter RJ, Tan DX, Manchester LC, et al. Medical implications of melatonin: receptor-mediated and receptor-independent actions. Adv Med Sci. 2007;52:11–28.

    PubMed  CAS  Google Scholar 

  45. Wyatt JK, Dijk DJ, Ritz-De Cecco A, et al. Sleep facilitating effect of exogenous melatonin in healthy young men and women is circadian-phase dependent. Sleep. 2006;29:609–18.

    PubMed  Google Scholar 

  46. Aeschbach D, Lockye Jr B, Dijk D-J, et al. Use of transdermal melatonin delivery to improve sleep maintenance during daytime. Clin Pharmacol Ther. 2009;864:378–82.

    Article  Google Scholar 

  47. Tokunaga S, Takeda Y, Shinomiya K, et al. Effects of some H1-antagonists on the sleep–wake cycle in sleep-disturbed rats. J Pharmacol Sci. 2007;103:201–6.

    Article  PubMed  CAS  Google Scholar 

  48. Richardson GS, Roehrs TA, Rosenthal L, et al. Tolerance to daytime sedative effects of H1 antihistamines. J Clin Psychopharmacol. 2002;22:511–5.

    Article  PubMed  CAS  Google Scholar 

  49. Mendelson WB. A review of the evidence for the efficacy and safety of trazodone in insomnia. J Clin Psychiatry. 2005;66:469–76.

    Article  PubMed  CAS  Google Scholar 

  50. Morin AK, Jarvis CI, Lynch AM. Therapeutic options for sleep maintenance and sleep-onset insomnia. Pharmacotherapy. 2007;27:89–110.

    Article  PubMed  CAS  Google Scholar 

  51. Schwartz T, Nihalani N, Virk S, et al. A comparison of the effectiveness of two hypnotic agents for the treatment of insomnia. Int J Psychiatr Nurs Res. 2004;10:1146–50.

    PubMed  Google Scholar 

  52. Ellenhorn MJ, Schonwald S, Ordog J, et al. Ellenhorn’s medical toxicology: diagnosis and treatment of human poisoning. 8th ed. Baltimore: Williams and Wilkins; 2006.

    Google Scholar 

  53. m-chlorophénylpipérazine nouvelle identification. Observatoire Francxais des Drogues et des Toxicomanies web site. 2006. Available at: http://www.drogues.gouv.fr/IMG/pdf/note_mCPP.pdf. Accessed 14 Mar 2006.

  54. Cankurtaran ES, Ozalp E, Soygur H, et al. Mirtazapine improves sleep and lowers anxiety and depression in cancer patients: superiority over imipramine. Support Care Cancer. 2008;16:1291–8.

    Article  PubMed  Google Scholar 

  55. Wiegand MH. Antidepressants for the treatment of insomnia: a suitable approach? Drugs. 2008;68:2411–7.

    Article  PubMed  CAS  Google Scholar 

  56. Miller DD. Atypical antipsychotics: sleep, sedation, and efficacy. J Clin Psychiatry. 2004;6:3–7.

    Google Scholar 

  57. Foldvary-Schaefer N, De Leon Sanchez I, Karafa M, et al. Gabapentin increases slow-wave sleep in normal adults. Epilepsia. 2002;43:1493–7.

    Article  PubMed  CAS  Google Scholar 

  58. Ehrenberg B. Importance of sleep restoration in co-morbid disease: effect of anticonvulsants. Neurology. 2000;54:S33–7.

    Article  PubMed  CAS  Google Scholar 

  59. Karam-Hage M, Brower KJ. Gabapentin treatment for insomnia associated with alcohol dependence [comment]. Am J Psychiatry. 2000;157:151.

    PubMed  CAS  Google Scholar 

  60. Bazil CW, Battista J, Basner RC. Gabapentin improves sleep in the presence of alcohol. J Clin Sleep Med. 2005;1:284–7.

    PubMed  Google Scholar 

  61. Lo HS, Yang CM, Lo HG, et al. Treatment effects of gabapentin for primary insomnia. Clin Neuropharmacol. 2010;33:84–90.

    Article  PubMed  CAS  Google Scholar 

  62. Hindmarch I, Dawson J, Stanley N. A double-blind study in healthy volunteers to assess the effects on sleep of pregabalin compared with alprazolam and placebo. Sleep. 2005;28:187–93.

    PubMed  Google Scholar 

  63. Dierks MR, Jordan JK, Sheehan AH. Prazosin treatment of nightmares related to posttraumatic stress disorder. Ann Pharmacother. 2007;41:1013–7.

    Article  PubMed  CAS  Google Scholar 

  64. Thompson CE, Taylor FB, McFall ME, et al. Nonnightmare distressed awakenings in veterans with posttraumatic stress disorder: response to prazosin. J Trauma Stress. 2008;21:417–20.

    Article  PubMed  Google Scholar 

  65. van Nieuwenhuijzen PS, McGregor IS, Hunt GE. The distribution of gamma-hydroxybutyrate-induced Fos expression in rat brain: comparison with baclofen. Neuroscience. 2009;158:441–55.

    Article  PubMed  Google Scholar 

  66. Black J, Pardi D, Hornfeldt CS, Inhaber N. The nightly administration of sodium oxybate results in significant reduction in the nocturnal sleep disruption of patients with narcolepsy. Sleep Med. 2009;10:829–35.

    Article  PubMed  Google Scholar 

  67. Monti JM, Jantos H. Effects of the serotonin 5-HT2A/2C receptor agonist DOI and of the selective 5-HT2A or 5-HT2C receptor antagonists EMD 281014 and SB-243213, respectively, on sleep and waking in the rat. Eur J Pharmacol. 2006;553:163–70.

    Article  PubMed  CAS  Google Scholar 

  68. Teegarden BR, Al Shamma H, Xiong Y. 5-HT2A inverse-agonists for the treatment of insomnia. Curr Top Med Chem. 2008;8:969–76.

    Article  PubMed  CAS  Google Scholar 

  69. Al-Shamma HA, Anderson C, Chuang E, et al. Nelotanserin, a novel selective human 5-hydroxytryptamine2A inverse agonist for the treatment of insomnia. J Pharmacol Exp Ther. 2010;332:281–90.

    Article  PubMed  CAS  Google Scholar 

  70. Kemp JA, Baur R, Sigel E. EVT 201: a high affinity, partial positive allosteric modulator of GABAA receptors with preference for the a1-subtype. Sleep. 2008;31:A34.

    Google Scholar 

  71. Boyle J, Stanley N, Hunneyball I, et al. A placebo controlled, randomised, double-blind, 5 way cross-over study of 4 doses of EVT 201 on subjective sleep quality and morning after performance in a traffic noise model of sleep disturbance. Sleep. 2007;30:A262.

    Google Scholar 

  72. Walsh JK, Salkeld L, Knowles LJ, et al. Treatment of elderly primary insomnia patients with EVT 201 improves sleep initiation, sleep maintenance, and daytime sleepiness. Sleep Med. 2010;11:23–30.

    Article  PubMed  Google Scholar 

  73. Neubauer DN. Almorexant, a dual orexin receptor antagonist for the treatment of insomnia. Curr Opin Investig Drugs. 2010;11:101–10.

    PubMed  CAS  Google Scholar 

  74. Hoever P, de Haas S, Winkler J, et al. Orexin receptor antagonism, a new sleep-promoting paradigm: an ascending single-dose study with almorexant. Clin Pharmacol Ther. 2010;87:593–600.

    Article  PubMed  CAS  Google Scholar 

  75. Smith HS, Barkin RL, Barkin SJ, et al. Personalized pharmacotheraphy for treatment approaches focused at primary insomnia. AM J Ther. 2011 May;18(3):227–40.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Anesthesiology, Albany Medical College, Albany Medical Center, 47 New Scotland Avenue, Albany, NY, 12159, USA

    Howard S. Smith M.D., FACP, FAAPM, FACNP

Authors
  1. Howard S. Smith M.D., FACP, FAAPM, FACNP
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Howard S. Smith M.D., FACP, FAAPM, FACNP .

Editor information

Editors and Affiliations

  1. The Center for Pain Relief, Inc., West Virginia University, 400 Court Street, Suite 100, Charleston, 25301, West Virginia, USA

    Timothy R. Deer

  2. Stanford Pain Management Center, Redwood City, CA, Clinic Chief, Stanford University School of Medicine, Stanford, 94065, California, USA

    Michael S. Leong

  3. Department of Anesthesiology, Rush Medical College, Professor, Rush University Medical Center, Chicago, 60612, Illinois, USA

    Asokumar Buvanendran

  4. Pennsylvania State University, College of Medicine, Department of Anesthesiology, Milton S. Hershey Medical Center, Hershey, 17033-0850, Pennsylvania, USA

    Vitaly Gordin

  5. Center for Interventional Pain and Spine, Newark, DE USA, Medical Director, Bryn Mawr Hospital, Bryn Mawr, 19010, Pennsylvania, USA

    Philip S. Kim

  6. President, National Institute of Pain, Tampa, 33558, Florida, USA

    Sunil J. Panchal

  7. The LITE Center, Clinical Associate Professor, Medical Director, School of Medicine, Miami, 33143, Florida, USA

    Albert L. Ray

Rights and permissions

Reprints and permissions

Copyright information

© 2013 American Academy of Pain Medicine

About this chapter

Cite this chapter

Smith, H.S. (2013). Sleep Aids. In: Deer, T., et al. Comprehensive Treatment of Chronic Pain by Medical, Interventional, and Integrative Approaches. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-1560-2_9

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-1560-2_9

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-1559-6

  • Online ISBN: 978-1-4614-1560-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation